rs2301612 — ADAMTS13 Q448E

ADAMTS13 Q448E — A Coding Variant in the VWF-Cleaving Enzyme

ADAMTS13¹¹ ADAMTS13
ADAM metallopeptidase with thrombospondin type 1 motif 13, the principal protease responsible for cleaving ultra-large von Willebrand factor (VWF) multimers in the circulation, encoded on chromosome 9q34.2 sits at the center of the VWF-platelet axis — a biological dial that determines whether platelet-rich microvascular thrombi form inappropriately. When ADAMTS13 activity is sufficient, it trims the hyper-adhesive VWF multimers released during vascular injury to safe sizes. When activity falls — through genetic variation, antibody-mediated inhibition, or acute-phase consumption — large multimers accumulate and recruit platelets into dangerous spontaneous aggregates. rs2301612 is a common missense variant in ADAMTS13 that substitutes glutamate for glutamine at position 448 (p.Gln448Glu, Q448E), placing a charged residue in a domain critical for enzyme conformation and activity.

The Mechanism

The Q448E substitution sits in the ADAMTS13 spacer domain — a region involved in substrate recognition, specifically in binding and positioning VWF for cleavage. Plaimauer et al. 2006²² Plaimauer et al. 2006
Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood. 2006;107(1):118-125. characterized Q448E using transfection experiments and found that Q448E alone has minor independent effects on ADAMTS13 secretion. However, its functional impact is highly context-dependent: in the presence of other common polymorphisms (P618A, A732V), Q448E acted as a positive modifier, partially rescuing secretion deficits — yet when co-occurring with the rare pathogenic mutation R1336W, Q448E enhanced the detrimental effect, driving ADAMTS13 activity to undetectable levels. This context-dependence means Q448E is not simply benign: its impact varies with the genetic background it inhabits.

In the largest GWAS of plasma ADAMTS13 levels, Ma et al. 2017³³ Ma et al. 2017
Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels. Blood Adv. 2017;1(18):1375-1388. identified rs2301612 as one of the coding variants in the top independent LD block at the ADAMTS13 locus that collectively explain 20% of plasma ADAMTS13 variance in 3,244 healthy individuals.

The Evidence

The clinical relevance of the G allele was examined directly in Warlo et al. 2022⁴⁴ Warlo et al. 2022
Genetic Variation in ADAMTS13 is Related to VWF Levels, Atrial Fibrillation and Cerebral Ischemic Events. Eur Heart J Suppl. 2022. — a study of 1,000 patients with chronic coronary syndrome followed for 2 years (106 clinical endpoints). The 1342G-allele (rs2301612 G) was associated with significantly higher rates of prior atrial fibrillation (P=.016) and prior cerebral ischemic events (P=.030). Notably, heterozygous CG carriers — not GG homozygotes — experienced more 2-year clinical endpoints than either homozygous group (P=.028). The same study found the SNPs did not measurably affect ADAMTS13 levels themselves, suggesting the mechanism operates through altered ADAMTS13 substrate-binding efficiency or interaction with co-occurring variants rather than gross protein concentration.

At the pathway level, higher genetically determined ADAMTS13 activity is protective: a Mendelian randomization study⁵⁵ Mendelian randomization study
Schooling CM et al. Atherosclerosis. 2019. using ADAMTS13 genetic instruments found that higher ADAMTS13 activity was inversely associated with ischemic heart disease (OR 0.91 per effect size, 95% CI 0.86–0.97), supporting a causal role for the ADAMTS13–VWF axis in coronary disease. The Rotterdam Study⁶⁶ Rotterdam Study
Sonneveld MA et al. J Thromb Haemost. 2016;14:2114-2120. (5,688 elderly participants, 456 CHD events) found that the lowest ADAMTS13 activity quartile carried HR 1.42 (95% CI 1.07–1.89) for incident CHD independent of VWF levels and traditional risk factors.

ClinVar classifies the isolated Q448E G allele as Benign/Likely benign for Upshaw-Schulman syndrome (VCV000242806, criteria provided, multiple submitters, no conflicts) — consistent with its high population frequency (~40% in Europeans). The pathogenic ClinVar entry (VCV000005813) refers specifically to the compound haplotype of Q448E + C508Y on the same chromosome in a TTP patient, not to Q448E in isolation.

Practical Actions

For G-allele carriers — especially CG heterozygotes who showed the strongest clinical endpoint signal in Warlo et al. — the most important actionable step is awareness of the VWF-ADAMTS13 axis and elimination of known ADAMTS13-suppressing behaviors. Tobacco smoking is the largest modifiable environmental factor reducing plasma ADAMTS13 (Ma et al. 2017). The G allele's context-dependent enzymatic effects make the genetic background especially relevant when additional ADAMTS13-impairing variants are present.

Interactions

Q448E sits within the same LD block as rs28673647, the top intronic ADAMTS13 activity variant. The compound effect of Q448E with the pathogenic R1336W mutation (Plaimauer 2006) demonstrates that coding variants in this gene can combine destructively — an important consideration when genetic testing reveals multiple ADAMTS13 variants. Co-occurring VWF-elevating variants (e.g., rs1063856) create an adverse VWF:ADAMTS13 ratio that amplifies thrombotic risk from any ADAMTS13-impairing variant. The 15-fold DVT risk observed with combined low ADAMTS13 activity and high VWF levels (Pagliari et al. 2021, Thromb Res) underscores the importance of interpreting rs2301612 alongside VWF status.